# Daniel C. Baumgart

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/daniel-c-baumgart/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,775 |
| Field | Inflammatory Bowel Disease |
| h-index | 56 |
| i10-index | 113 |
| Last Known Institution | University of Alberta |
| OpenAlex ID | https://openalex.org/A5042526092 |
| ORCID iD | https://orcid.org/0000-0003-2146-507X |
| Works | 298 |

## Researcher papers

- [ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications](https://scholariq.org/papers/ecco-esgar-guideline-for-diagnostic-assessment-in-ibd-part-1-initial-diagnosis/)
- [The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations](https://scholariq.org/papers/the-second-european-evidence-based-consensus-on-the-diagnosis-and-management-of/)
- [Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines](https://scholariq.org/papers/imaging-techniques-for-assessment-of-inflammatory-bowel-disease-joint-ecco-and/)
- [Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease](https://scholariq.org/papers/long-term-efficacy-and-safety-of-stem-cell-therapy-cx601-for-complex-perianal/)
- [ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects](https://scholariq.org/papers/ecco-esgar-guideline-for-diagnostic-assessment-in-ibd-part-2-ibd-scores-and/)
- [Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection](https://scholariq.org/papers/infliximab-reduces-endoscopic-but-not-clinical-recurrence-of-crohn-s-disease/)
- [Use of Intestinal Ultrasound to Monitor Crohn’s Disease Activity](https://scholariq.org/papers/use-of-intestinal-ultrasound-to-monitor-crohn-s-disease-activity/)
- [Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study](https://scholariq.org/papers/vedolizumab-provides-clinical-benefit-over-1-year-in-patients-with-active/)

## Researcher topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Eosinophilic Esophagitis](https://scholariq.org/topics/eosinophilic-esophagitis/)
- [Gut microbiota and health](https://scholariq.org/topics/gut-microbiota-and-health/)
- [Pregnancy and Medication Impact](https://scholariq.org/topics/pregnancy-and-medication-impact/)

## Researcher university

- [University of Alberta](https://scholariq.org/institutions/university-of-alberta/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.